Chondroitin sulfate CS b-Bioactive was found to be superior to an anti-inflammatory drug (celecoxib) for delaying the progression of knee osteoarthritis, according to new research presented at the Annual meeting of the American Academy of Rheumatology in San Francisco, CA.
 
The multicenter, randomized, double-blind, controlled and comparative study analyzed chondroitin sulfate and celecoxib over the course of three years. The study, named MOSAIC (24 MOnth study on Structural changes in knee osteoarthritis Assessed by mrI with Chondroitin sulphate), was carried out in five medical centers in Quebec (Canada) and sponsored by Bioiberica. The study recruited 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain. Participants were divided into two groups: the first group received 1,200 mg of pharmaceutical grade chondroitin sulfate (CS b-Bioactive, made by Bioiberica) per day, while the second group received 200 mg of celecoxib (made by Pfizer) per day, over a two-year period. The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, a second one after one year, and a third one at the end of the study. The main aim was to assess the effects of chondroitin sulfate CS b-Bioactive and celecoxib over the loss of cartilage volume in knee osteoarthritis after 24 months by means of Quantitative Magnetic Resonance.  
 
 “There has been much talk about the efficacy of chondroitin sulfate in osteoarthritis and we believed that it was about time to use the latest imaging techniques available to assess its efficacy. Osteoarthritis is characterized by the progressive wear and tear of the cartilage, and the magnetic resonance technique allows one to precisely assess the loss of cartilage, and therefore, the disease’s progression. This is the main new feature of this study-until now, long term studies like this one could only use radiography,”explained Professor Jean Pierre Pelletier.
 
The results revealed that the progression of knee osteoarthritis is slower in patients receiving chondroitin sulfate CS b-Bioactive. More precisely, this group experienced a statistically significant lower loss of cartilage volume after the first year of treatment, in comparison with those patients who received the anti inflammatory drug. “This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and that it had a disease-modifying effect,” affirmed Professor Pelletier.
 
The study also evaluated the effects of both products on the disease’s symptoms. More precisely, the study evaluated their effects on pain, function, stiffness, joint efflux and swelling; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50%. “The study confirmed that both products are efficient for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect and a better safety profile,” declared Professor Pelletier. Dr. Josep Vergés, medical and scientific director at Bioberica, added that, “this study shows that chondroitin sulfate complies with the requirements that an osteoarthritis treatment must fulfill: on one hand, it improves pain and functional capacity, and, on the other hand, it delays the disease’s progression while having a good safety profile, something essential in a chronic disease such as osteoarthritis.”
 
For more information: www.bioiberica.com